EP0911398A3 - Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease - Google Patents
Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease Download PDFInfo
- Publication number
- EP0911398A3 EP0911398A3 EP98121175A EP98121175A EP0911398A3 EP 0911398 A3 EP0911398 A3 EP 0911398A3 EP 98121175 A EP98121175 A EP 98121175A EP 98121175 A EP98121175 A EP 98121175A EP 0911398 A3 EP0911398 A3 EP 0911398A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- tau protein
- epitopes
- alzheimer
- diagnosis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013498 tau Proteins Human genes 0.000 title abstract 5
- 108010026424 tau Proteins Proteins 0.000 title abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 230000026731 phosphorylation Effects 0.000 title abstract 2
- 238000006366 phosphorylation reaction Methods 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98121175A EP0911398B1 (en) | 1991-12-06 | 1992-12-07 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
EP08010527A EP2009104A1 (en) | 1991-12-06 | 1992-12-07 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91120974A EP0544942A1 (en) | 1991-12-06 | 1991-12-06 | Novel tools for the diagnosis and treatment of Alzheimer disease |
EP91120974 | 1991-12-06 | ||
EP92119551 | 1992-11-16 | ||
EP92119551 | 1992-11-16 | ||
EP98121175A EP0911398B1 (en) | 1991-12-06 | 1992-12-07 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
EP93901671A EP0618968B1 (en) | 1991-12-06 | 1992-12-07 | Tools for the diagnosis and treatment of alzheimer's disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93901671A Division EP0618968B1 (en) | 1991-12-06 | 1992-12-07 | Tools for the diagnosis and treatment of alzheimer's disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08010527A Division EP2009104A1 (en) | 1991-12-06 | 1992-12-07 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0911398A2 EP0911398A2 (en) | 1999-04-28 |
EP0911398A3 true EP0911398A3 (en) | 2003-02-26 |
EP0911398B1 EP0911398B1 (en) | 2008-06-11 |
Family
ID=26129111
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98121177A Expired - Lifetime EP0909814B1 (en) | 1991-12-06 | 1992-12-07 | Use of protein kinases for the diagnosis and treatment of Alzheimer's disease |
EP98121175A Expired - Lifetime EP0911398B1 (en) | 1991-12-06 | 1992-12-07 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
EP08010527A Withdrawn EP2009104A1 (en) | 1991-12-06 | 1992-12-07 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
EP93901671A Revoked EP0618968B1 (en) | 1991-12-06 | 1992-12-07 | Tools for the diagnosis and treatment of alzheimer's disease |
EP98121176A Expired - Lifetime EP0911390B1 (en) | 1991-12-06 | 1992-12-07 | Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98121177A Expired - Lifetime EP0909814B1 (en) | 1991-12-06 | 1992-12-07 | Use of protein kinases for the diagnosis and treatment of Alzheimer's disease |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08010527A Withdrawn EP2009104A1 (en) | 1991-12-06 | 1992-12-07 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
EP93901671A Revoked EP0618968B1 (en) | 1991-12-06 | 1992-12-07 | Tools for the diagnosis and treatment of alzheimer's disease |
EP98121176A Expired - Lifetime EP0911390B1 (en) | 1991-12-06 | 1992-12-07 | Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease |
Country Status (10)
Country | Link |
---|---|
US (2) | US6200768B1 (en) |
EP (5) | EP0909814B1 (en) |
JP (4) | JPH07507044A (en) |
AT (4) | ATE398176T1 (en) |
AU (2) | AU681071B2 (en) |
CA (1) | CA2125298A1 (en) |
DE (4) | DE69230148T2 (en) |
DK (1) | DK0618968T3 (en) |
ES (2) | ES2302343T3 (en) |
WO (1) | WO1993011231A1 (en) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010913A (en) * | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
JPH06239899A (en) * | 1993-02-12 | 1994-08-30 | Teijin Ltd | Antibody for human tau protein and determination of human tau protein in body fluid utilizing the same |
GB2295395B (en) * | 1993-08-12 | 1998-04-01 | Inst Of Psychiatry | Models of Alzheimer's disease |
GB9316727D0 (en) * | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
CA2178212C (en) * | 1993-12-21 | 2011-06-14 | Marc Vandermeeren | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
WO1996004309A1 (en) * | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
GB9610829D0 (en) | 1996-05-23 | 1996-07-31 | Medical Res Council | Screening of agents for treatment of azlheimers disease |
EP1009853B1 (en) * | 1997-09-04 | 2006-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Assays for detecting modulators of cytoskeletal function |
US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
US6797478B1 (en) * | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
AR023052A1 (en) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | DERIVATIVES OF PIRIMIDONA |
US20020002270A1 (en) * | 1999-06-16 | 2002-01-03 | Raymond P. Zinkowski | Purified antigen for alzheimer's disease, and methods of obtaining and using same |
US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
KR100960256B1 (en) | 2001-02-27 | 2010-06-01 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
EP1925315A3 (en) * | 2001-02-27 | 2009-11-18 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
KR100754596B1 (en) | 2001-09-21 | 2007-09-05 | 미쯔비시 웰 파마 가부시키가이샤 | 3-substituted-4-pyrimidone derivatives |
CA2460121C (en) | 2001-09-21 | 2010-11-02 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
CA2477604A1 (en) * | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
KR20050000409A (en) * | 2002-04-25 | 2005-01-03 | 브레인스게이트 리미티드 | Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
EP1585430B1 (en) * | 2002-11-14 | 2017-01-11 | Brainsgate Ltd. | Surgical tools and techniques for stimulation |
JP4616003B2 (en) | 2002-12-16 | 2011-01-19 | 田辺三菱製薬株式会社 | 3-substituted-4-pyrimidone derivatives |
AU2003296663A1 (en) * | 2002-12-18 | 2004-07-09 | Novartis Ag | Endothelial cell specifically binding peptides |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
GB2398533B (en) * | 2003-02-19 | 2005-11-16 | Gillette Co | Safety razors |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
WO2005058374A1 (en) * | 2003-12-15 | 2005-06-30 | Tongji Medical Center | Methods and compositions for modulating tau in vivo |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US20090299418A1 (en) * | 2004-08-23 | 2009-12-03 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
JP5186212B2 (en) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | Method for chemical synthesis and purification of diaminophenothiazinium compounds such as methylthioninium chloride (MTC) |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
EP1843734A4 (en) * | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | Compositions and methods for enhancing cognitive function |
US20070134724A1 (en) * | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
KR101667623B1 (en) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
PL1954718T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
DK2013191T6 (en) | 2006-03-29 | 2019-04-23 | Wista Lab Ltd | 3,7-Diamino-10H-phenothiazine salts and their use |
CA2645946C (en) | 2006-03-29 | 2014-04-01 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20110086908A9 (en) * | 2007-01-22 | 2011-04-14 | Roger Nitsch | Use of phosphatase inhibitors for the treatment of neurodegenerative diseases |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
EP2669386A1 (en) | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of alzheimer's disease |
ES2683021T3 (en) | 2008-07-28 | 2018-09-24 | Blanchette Rockefeller Neurosciences Institute | PKC activating compounds for the treatment of neurodegenerative diseases |
US9464122B2 (en) * | 2008-08-20 | 2016-10-11 | Oligomerix, Inc. | Methods and compositions comprising tau oligomers |
WO2010021755A2 (en) * | 2008-08-20 | 2010-02-25 | Oligomerix, Inc. | Tau protease compositions and methods |
FR2940972B1 (en) | 2009-01-09 | 2015-07-31 | Isp Investments Inc | NOVEL ANTI-AGING PEPTIDES AND COSMETIC AND / OR PHARMACEUTICAL COMPOSITION CONTAINING SAME |
EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
NZ598356A (en) * | 2009-07-30 | 2014-06-27 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
WO2011026031A1 (en) * | 2009-08-28 | 2011-03-03 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
CN102549438B (en) | 2009-09-24 | 2014-10-29 | 国家健康与医学研究院 | FKBP52-TAU interaction as a novel therapeutical target for treating the neurological disorders involving TAU dysfunction |
US20110144029A1 (en) * | 2009-09-30 | 2011-06-16 | Board Of Regents, The University Of Texas System | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases |
WO2011041761A1 (en) | 2009-10-02 | 2011-04-07 | Blanchette Rockefeller Neurosciences Institute | Fibroblast growth patterns for diagnosis of alzheimer's disease |
MX336196B (en) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Amyloid-beta binding proteins. |
MX358739B (en) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Amyloid-beta binding proteins. |
CA2812865C (en) | 2010-10-07 | 2021-01-26 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
CA2817973C (en) | 2010-10-15 | 2019-06-25 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
CN105853439A (en) | 2011-02-11 | 2016-08-17 | 维斯塔实验室有限公司 | Phenothiazine diaminium salts and their use |
KR20140038396A (en) | 2011-04-28 | 2014-03-28 | 우니베르지태트 라이치히 | Polymutant tau protein variants and their use for recapitulating human tauopathies |
US9506051B2 (en) | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
CN109265543B (en) * | 2011-09-19 | 2022-04-26 | 阿克松神经系统科学公司 | Protein-based therapy and diagnosis of TAU protein-mediated pathologies in alzheimer's disease |
CN104080806B (en) | 2011-10-07 | 2018-01-19 | Ac免疫有限公司 | Identify Tau phosphorylation specific antibody |
EP2780316B1 (en) | 2011-11-13 | 2020-04-15 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
WO2014008404A1 (en) | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
WO2014141124A1 (en) * | 2013-03-13 | 2014-09-18 | Institut National De La Sante Et De La Recherche Medicale | Erk-pathway activating compound for preventing or treating leptin resistance |
RU2661111C2 (en) | 2013-03-15 | 2018-07-11 | Ац Иммуне С.А. | Anti-tau antibodies and methods of use |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
CA2932958A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
TWI734975B (en) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | Humanized anti-tau antibodies |
CN107073297B (en) | 2014-07-08 | 2021-09-14 | 纽约大学 | Tau imaging ligands and their use in diagnosis and treatment of tauopathies |
WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
PL3313877T3 (en) | 2015-06-24 | 2020-11-02 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
JP6913078B2 (en) | 2015-08-13 | 2021-08-04 | ニューヨーク・ユニバーシティ | Antibody-based molecules specific for the shortened Asp421 epitope of tau, and their use in the diagnosis and treatment of tau dysfunction. |
KR20230161532A (en) | 2015-11-24 | 2023-11-27 | 메사추세츠 인스티튜트 오브 테크놀로지 | Systems and methods for preventing, mitigating, and/or treating dementia |
JOP20200228A1 (en) | 2015-12-21 | 2017-06-16 | Novartis Ag | Compositions and methods for decreasing tau expression |
PE20190227A1 (en) | 2016-07-12 | 2019-02-13 | H Lundbeck As | SPECIFIC ANTIBODIES FOR HYPERPHOSPHORILATED TAU AND THEIR METHODS OF USE |
US10995137B2 (en) | 2017-01-04 | 2021-05-04 | H. Lundbeck A/S | Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases |
KR20220146710A (en) | 2017-10-10 | 2022-11-01 | 메사추세츠 인스티튜트 오브 테크놀로지 | Systems and methods for preventing, mitigating, and/or treating dementia |
KR20230015501A (en) * | 2017-10-10 | 2023-01-31 | 메사추세츠 인스티튜트 오브 테크놀로지 | Treating dementia with visual stimulation to synch gamma oscillations in brain |
US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0303555A2 (en) * | 1987-08-11 | 1989-02-15 | Dr. Franz Köhler Chemie GmbH | Preparation of a metallic chelate of ethanol aminophosphoric acid and medicament |
WO1989003993A1 (en) * | 1987-10-19 | 1989-05-05 | Medical Research Council | Paired helical filament core and antibody thereto useful in diagnosing alzheimer's disease |
US4874694A (en) * | 1987-04-07 | 1989-10-17 | The Rockefeller University | Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders |
EP0457295A2 (en) * | 1990-05-16 | 1991-11-21 | The Rockefeller University | Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease |
WO1993003148A2 (en) * | 1991-08-09 | 1993-02-18 | Massachusetts Institute Of Technology | Tau/neurofilament protein kinases pk40 and pk36 |
WO1996013592A2 (en) * | 1994-10-28 | 1996-05-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein kinase npk-110 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE911869A1 (en) * | 1990-06-01 | 1991-12-04 | Regeneron Pharma | A family of map2 protein kinases |
DE4028970A1 (en) | 1990-09-12 | 1992-03-19 | Kettner Verpackungsmaschf | TRANSPORT ROLE |
-
1992
- 1992-12-07 US US08/244,603 patent/US6200768B1/en not_active Expired - Lifetime
- 1992-12-07 ES ES98121177T patent/ES2302343T3/en not_active Expired - Lifetime
- 1992-12-07 CA CA002125298A patent/CA2125298A1/en not_active Abandoned
- 1992-12-07 EP EP98121177A patent/EP0909814B1/en not_active Expired - Lifetime
- 1992-12-07 EP EP98121175A patent/EP0911398B1/en not_active Expired - Lifetime
- 1992-12-07 DE DE69230148T patent/DE69230148T2/en not_active Expired - Fee Related
- 1992-12-07 ES ES93901671T patent/ES2136654T3/en not_active Expired - Lifetime
- 1992-12-07 AT AT98121175T patent/ATE398176T1/en not_active IP Right Cessation
- 1992-12-07 WO PCT/EP1992/002829 patent/WO1993011231A1/en not_active Application Discontinuation
- 1992-12-07 DK DK93901671T patent/DK0618968T3/en active
- 1992-12-07 AT AT98121176T patent/ATE438716T1/en not_active IP Right Cessation
- 1992-12-07 EP EP08010527A patent/EP2009104A1/en not_active Withdrawn
- 1992-12-07 EP EP93901671A patent/EP0618968B1/en not_active Revoked
- 1992-12-07 JP JP5509840A patent/JPH07507044A/en active Pending
- 1992-12-07 DE DE69233767T patent/DE69233767D1/en not_active Expired - Lifetime
- 1992-12-07 AT AT98121177T patent/ATE386115T1/en not_active IP Right Cessation
- 1992-12-07 AT AT93901671T patent/ATE185599T1/en not_active IP Right Cessation
- 1992-12-07 AU AU32560/93A patent/AU681071B2/en not_active Ceased
- 1992-12-07 DE DE69233736T patent/DE69233736D1/en not_active Expired - Lifetime
- 1992-12-07 DE DE69233723T patent/DE69233723T2/en not_active Expired - Lifetime
- 1992-12-07 EP EP98121176A patent/EP0911390B1/en not_active Expired - Lifetime
-
1997
- 1997-07-10 AU AU28656/97A patent/AU707736B2/en not_active Ceased
-
1999
- 1999-05-19 JP JP11139268A patent/JP2000026498A/en active Pending
- 1999-05-19 JP JP11139314A patent/JP2000032983A/en active Pending
- 1999-05-19 JP JP11139294A patent/JP2000037188A/en active Pending
-
2008
- 2008-08-04 US US12/185,319 patent/US20090162336A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4874694A (en) * | 1987-04-07 | 1989-10-17 | The Rockefeller University | Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders |
EP0303555A2 (en) * | 1987-08-11 | 1989-02-15 | Dr. Franz Köhler Chemie GmbH | Preparation of a metallic chelate of ethanol aminophosphoric acid and medicament |
WO1989003993A1 (en) * | 1987-10-19 | 1989-05-05 | Medical Research Council | Paired helical filament core and antibody thereto useful in diagnosing alzheimer's disease |
EP0457295A2 (en) * | 1990-05-16 | 1991-11-21 | The Rockefeller University | Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease |
WO1993003148A2 (en) * | 1991-08-09 | 1993-02-18 | Massachusetts Institute Of Technology | Tau/neurofilament protein kinases pk40 and pk36 |
WO1996013592A2 (en) * | 1994-10-28 | 1996-05-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein kinase npk-110 |
Non-Patent Citations (12)
Title |
---|
AIZAWA H, KAWASAKI H, MUROFUSHI H, KOTANI S, SUZUKI K, SAKAI H.: "Microtubule-binding domain of tau proteins.", J BIOL CHEM 1988 JUN 5;263(16):7703-7, XP002226001 * |
BIERNAT ET AL.: "The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region", EMBO JOURNAL, vol. 11, no. 4, 4 April 1992 (1992-04-04), EYNSHAM, OXFORD GB, pages 1593 - 1597, XP001109363 * |
BRION JP, HANGER DP, COUCK AM, ANDERTON BH.: "A68 proteins in Alzheimer's disease are composed of several tau isoforms in a phosphorylated state which affects their electrophoretic mobilities.", BIOCHEM J 1991 NOV 1;279 ( PT 3):831-6, XP002226002 * |
GOEDERT M ET AL: "CLONING AND SEQUENCING OF THE CDNA ENCODING A CORE PROTEIN OF THE PAIRED HELICAL FILAMENT OF ALZHEIMER DISEASE: IDENTIFICATION AS THEMICROTUBULE-ASSOCIATED PROTEIN TAU", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 85, June 1988 (1988-06-01), pages 4051 - 4055, XP002942590, ISSN: 0027-8424 * |
GUSTKE N, STEINER B, MANDELKOW EM, BIERNAT J, MEYER HE, GOEDERT M, MANDELKOW E.: "The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs.", FEBS LETT. 1992 JUL 28;307(2):199-205., XP001127472 * |
ISHIGURO K. ET AL.: "A serine/threonine proline kinase activity is included in the tau protein kinase fraction forming a paired helical filament epitope", NEUROSCIENCE LETTERS, vol. 128, July 1991 (1991-07-01), pages 195 - 198, XP001131938 * |
LEDESMA M D ET AL: "IMPLICATION OF BRAIN CDC2 AND MAP2 KINASES IN THE PHOSPHORYLATION OF TAU PROTEIN IN ALZHEIMER'S DISEASE", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 308, no. 2, 17 August 1992 (1992-08-17), pages 218 - 224, XP000371843, ISSN: 0014-5793 * |
LEE V M-Y ET AL: "A68: A MAJOR SUBUNIT OF PAIRED HELICAL FILAMENTS AND DERIVATIZED FORMS OF NORMAL TAU", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 251, 8 February 1991 (1991-02-08), pages 675 - 678, XP002001385, ISSN: 0036-8075 * |
LICHTENBERG-KRAAG B. ET AL.: "alzheimer-type phosphorylation of microtubule -associated protein tau in vitro", THE JOURNAL OF CELL BIOLOGY., vol. 115, no. 3, 8 December 1991 (1991-12-08), LER UNIVERSITY PRESS US, pages 2, XP001131910 * |
LICHTENBERG-KRAAG, B. ET AL.: "'Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, no. 12, June 1992 (1992-06-01), WASHINGTON US, pages 5384 - 5388, XP002226003 * |
RODER H M ET AL: "TWO NOVEL KINASES PHOSPHORYLATE TAU AND THE KSP SITE OF HEAVY NEUROFILAMENT SUBUNITS IN HIGH STOICHIOMETRIC RATIOS", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 11, no. 11, 1 November 1991 (1991-11-01), pages 3325 - 3343, XP000579111, ISSN: 0270-6474 * |
UÉDA K ET AL: "ALZ-50 RECOGNIZES A PHOSPHORYLATED EPITOPE OF TAU PROTEIN", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 10, no. 10, 1 October 1990 (1990-10-01), pages 3295 - 3304, XP000600531, ISSN: 0270-6474 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0911398A3 (en) | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease | |
CA2260769A1 (en) | Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg | |
CA2121599A1 (en) | Monoclonal antibodies directed against the microtubule-associated protein tau | |
ATE165395T1 (en) | TUMOR GROWTH INHIBITORS FROM TISSUES, METHODS OF THEIR PRODUCTION AND USES | |
EP1361229A3 (en) | Use of Tyrosine Kinase (PYK2) to produce antibodies | |
EP0378924A3 (en) | Detection of neurological disease or dysfunction | |
WO2001087354A3 (en) | Use of small molecule radioligands for diagnostic imaging | |
WO1995014781A3 (en) | Methods for diagnosing early lyme disease | |
WO1993021321A3 (en) | T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA) | |
WO1996013592A3 (en) | Protein kinase npk-110 | |
WO2001029217A3 (en) | Novel polypeptides and polynucleotides encoding same | |
WO2002000691A3 (en) | Polynucleotides and polypeptides encoded thereby | |
AU2579995A (en) | Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis | |
NO950526L (en) | T-cell epitopes of raigress pollen allergen | |
CA2259141A1 (en) | Treatment and diagnosis of infections of gram positive cocci | |
EP0780472A3 (en) | Stress proteins | |
CA2160121A1 (en) | T cell epitopes of the major allergens from dermatophagoides (house dust mite) | |
AU7275891A (en) | Synthetic peptides which contain sequences from factor viia, and the use thereof | |
CA2151945A1 (en) | Assay and treatment for demyelinating diseases such as multiple sclerosis | |
FI963331A (en) | T-cell epitopes of major allergens from dermatophagoides (room dust mites) | |
NO941458L (en) | ||
MX9800191A (en) | Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 618968 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STEINER, BARBARA Inventor name: LICHTENBERG-KRAAG, BIRGIT Inventor name: BIEMAT, JACEK Inventor name: DREWES, GERARD Inventor name: MANDELKOW, ECKHARD Inventor name: MANDELKOW, EVA-MARIA |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 20030826 |
|
17Q | First examination report despatched |
Effective date: 20031128 |
|
17Q | First examination report despatched |
Effective date: 20031128 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STEINER, BARBARA Inventor name: LICHTENBERG-KRAAG, BIRGIT Inventor name: BIERNAT, JACEK Inventor name: DREWES, GERARD Inventor name: MANDELKOW, ECKHARD Inventor name: MANDELKOW, EVA-MARIA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENS |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0618968 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69233736 Country of ref document: DE Date of ref document: 20080724 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080911 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081111 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
26N | No opposition filed |
Effective date: 20090312 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081231 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20081207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20090831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081231 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081207 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080912 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20120130 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69233736 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69233736 Country of ref document: DE |